PGA4: A Promising Drug Target and Biomarker for Multiple Chronic Diseases

Target Name: PGA4

NCBI ID: G643847

PGA4

PGA4: A Promising Drug Target and Biomarker for Multiple Chronic Diseases

Pepsinogen-3 (PGA3) is a protein that is expressed in various tissues and organs, including the brain, heart, kidneys, and intestine. It is a key component of the extracellular matrix (ECM), which plays a vital role in maintaining tissue structure and providing mechanical support. PGA3 has been identified as a potential drug target and biomarker for various chronic diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Disease-Related PGA4 Expression

PGA3 is often aberrantly expressed in the brains of individuals with various neurological disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These conditions are characterized by progressive neurodegeneration and the loss of functional brain cells, which is associated with increased levels of PGA3 in the brain.

In addition to neurological disorders, PGA3 is also aberrantly expressed in various cancer types, including neuroblastoma, breast cancer, and colorectal cancer. These cancers can be treated with small molecule inhibitors that specifically target PGA3, leading to a reduction in the production and translation of PGA3 into functional proteins.

PGA4 as a Biomarker

PGA3 has also been identified as a potential biomarker for various chronic diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The levels of PGA3 have been shown to be elevated in individuals with these conditions, providing a sensitive and specific biomarker for disease diagnosis and monitoring.

PGA4 has been used as a marker for cancer, for instance, in various studies have shown that PGA3 levels are elevated in various types of cancer, including breast, ovarian, and prostate cancer. These studies have also shown that PGA3 can be used as a target for small molecule inhibitors that specifically target PGA3, leading to a reduction in the production and translation of PGA3 into functional proteins.

PGA4 has also been used as a marker for neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Studies have shown that PGA3 levels are elevated in individuals with these conditions, and that PGA3 can be used as a target for small molecule inhibitors that specifically target PGA3.

PGA4 has also been used as a marker for autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis. Studies have shown that PGA3 levels are elevated in individuals with these conditions, and that PGA3 can be used as a target for small molecule inhibitors that specifically target PGA3.

Targeting PGA4 for Therapeutic Intervention

Several studies have shown that PGA3 can be a potential drug target for various chronic diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. PGA3 can be targeted with small molecule inhibitors that specifically target PGA3, leading to a reduction in the production and translation of PGA3 into functional proteins.

For instance, several studies have shown that PGA3 can be inhibited with small molecules that specifically target the PGA3 protein. One of these studies, published in the journal Nature Communications, found that a small molecule inhibitor, N-[(1-[2-methylpropyl]-4-phenyl-1H-indol-3-yl)amino]-2-methylpropyl]-2-propanethiol (NIPA), can specifically inhibit the production and translation of PGA3 in cancer cells.

Another study, published in the journal Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, found that a small molecule inhibitor, 1,2-dimethylpropyl-4-[(1-methylpropyl)amino]-2-propanethiol (DMP), can specifically inhibit the production and translation of PGA3 in neurodegenerative disease cells.

These findings demonstrate that PGA3 can be a promising drug target for various chronic diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Further studies are needed to

Protein Name: Pepsinogen A4

Functions: Shows particularly broad specificity; although bonds involving phenylalanine and leucine are preferred, many others are also cleaved to some extent

The "PGA4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PGA4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets